Can the effectiveness of hypertension management be improved?

References

• Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371(9623), 1513–1518 (2008).
   PubMed Web of Science ®Google Scholar
• Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 360(9343), 1347–1360 (2002).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Perera GA. Hypertensive vascular disease; description and natural history. J. Chronic Dis. 1(1), 33–42 (1955).
   PubMedGoogle Scholar
• Ruilope LM. Current challenges in the clinical management of hypertension. Nat. Rev. Cardiol. 9(5), 267–275 (2012).
   Web of Science ®Google Scholar
• Erdine S. How well is hypertension controlled in Europe? ESH Scientific Newsletter 12(3), 5–6 (2011).
   Google Scholar
• Lindholm LH. The problem of uncontrolled hypertension. J. Hum. Hypertens. 16(Suppl. 3), S3–S8 (2002).
   Google Scholar
• Basile J. The importance of prompt blood pressure control. J. Clin. Hypertens. (Greenwich) 10(1 Suppl. 1), 13–19 (2008).
   PubMed Web of Science ®Google Scholar
• Berlowitz DR, Franklin S. The clock is ticking: the case for achieving more rapid control of hypertension. J. Clin. Hypertens. (Greenwich) 12(5), 323–327 (2010).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25(9), 1751–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305(9), 913–922 (2011).
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G. Management of essential hypertension. Br. Med. Bull. 94, 189–199 (2010).
   PubMedGoogle Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 27(5), 923–934 (2009).
   PubMed Web of Science ®Google Scholar
• NICE. Hypertension: the clinical management of primary hypertension in adults. Update of clinical guidelines 18 and 34. London College of Physicians, UK (2011).
   Google Scholar
• Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358(18), 1887–1898 (2008).
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J. Am. Coll. Cardiol. 57(20), 2037–2114 (2011).
   PubMed Web of Science ®Google Scholar
• Barengo NC, Tuomilehto JO. Blood pressure treatment target in patients with diabetes mellitus–current evidence. Ann. Med. 44(Suppl. 1), S36–S42 (2012).
   PubMed Web of Science ®Google Scholar
• McBrien K, Rabi DM, Campbell N et al. Intensive and standard blood pressure targets in patients with Type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med. 172(17), 1296–1303 (2012).
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 36(Suppl. 1), S11–S66 (2013).
   PubMed Web of Science ®Google Scholar
• O’Brien E. Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J. Intern. Med. 269(5), 478–495 (2011).
   PubMed Web of Science ®Google Scholar
• Celis H, Den Hond E, Staessen JA. Self-measurement of blood pressure at home in the management of hypertension. Clin. Med. Res. 3(1), 19–26 (2005).
   PubMedGoogle Scholar
• Puig JG, Ruilope LM, Ortega R. Antihypertensive treatment efficacy in Type II diabetes mellitus. Dissociation between casual and 24-hour ambulatory blood pressure. Spanish Multicenter Study Group. Hypertension 26(6 Pt 2), 1093–1099 (1995).
   PubMedGoogle Scholar
• Banegas JR, Messerli FH, Waeber B et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am. J. Med. 122(12), 1136–1141 (2009).
   PubMedGoogle Scholar
• Zanchetti A, Mancia G, Black HR et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J. Hypertens. 27(4), 673–679 (2009).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Bakris GL. Therapeutic Strategies in Hypertension. Clinical Publishing, Oxford, UK (2006).
   Google Scholar
• de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57(5), 898–902 (2011).
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ. Hydrochlorothiazide: is it a wise choice? Expert Opin. Pharmacother. 13(6), 807–814 (2012).
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Goerdt CJ et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47(3), 352–358 (2006).
   PubMed Web of Science ®Google Scholar
• Kountz DS, Goldman A, Mikhail J, Ezer M. Chlorthalidone: the forgotten diuretic. Postgrad. Med. 124(1), 60–66 (2012).
   PubMed Web of Science ®Google Scholar
• Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 57(4), 689–694 (2011).
   PubMed Web of Science ®Google Scholar
• Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat. Rev. Cardiol. 9(5), 276–285 (2012).
   PubMed Web of Science ®Google Scholar
• Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 380(9841), 591–600 (2012).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375(9722), 1255–1266 (2010).
   PubMed Web of Science ®Google Scholar
• Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J. Pharmacol. Exp. Ther. 336(3), 801–808 (2011).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sica D, Weber M et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J. Clin. Hypertens. (Greenwich) 13(2), 81–88 (2011).
   PubMed Web of Science ®Google Scholar
• Sica D, White WB, Weber MA et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J. Clin. Hypertens. (Greenwich) 13(7), 467–472 (2011).
   PubMed Web of Science ®Google Scholar
• White WB, Weber MA, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 57(3), 413–420 (2011).
   PubMed Web of Science ®Google Scholar
• Bonner G, Bakris GL, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J. Hum. Hypertens. doi:10.1038/jhh.2013.6 (2013) (Epub ahead of print).
   Google Scholar
• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756), 1903–1909 (2010).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Volpe M. The case for blood pressure control in risk groups. Int. J. Clin. Pract. 58(9), 844–849 (2004).
   PubMedGoogle Scholar
• Rydén L, Waeber B, Ruilope LM et al. The management of the Type 2 diabetic patient with hypertension - too late and too little: suggested improvements. Blood Press. 17(5–6), 250–259 (2008).
   PubMed Web of Science ®Google Scholar
• Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 59(2), 331–338 (2012).
   PubMed Web of Science ®Google Scholar
• Taylor JG, Bisognano JD. Baroreflex stimulation in antihypertensive treatment. Curr. Hypertens. Rep. 12(3), 176–181 (2010).
   PubMedGoogle Scholar